![]() ![]() For the LC Plus nebulizer, FPF 5.8 was 92.3 ± 0.1 and FPF 3.3 was 67.0 ± 0.7 during the first sampling period. The Acorn II nebulizer delivered a fine particle fraction FPF 5.8 (%<5.8 μm) of 92.5 ± 0.8 and FPF 3.3 (%<3.3 μm) of 82.3 ± 2.1 during the first sampling period. The concentration of micafungin sodium increased by 21% when delivered by the Acorn II nebulizer and by 20% when delivered by the LC Plus nebulizer, respectively, from the first to the second sampling period. In the present pilot study, we characterize the performance of two nebulizers and their potential for delivering micafungin to the lungs as well as the use of multivariate data analysis for mass distribution profile comparison. Pulmonary delivery of micafungin has not previously been reported. Micafungin (Astellas Pharma US, Deerfield, IL, USA) has been shown to be an effective antifungal agent when administrated intravenously. A contextually relevant message maximizes the outcomes of POC communications, hence is an ideal resource for script generation.Pharmaceutical aerosols have been targeted to the lungs for the treatment of asthma and pulmonary infectious diseases successfully. Targeting HCPs with brand messages during their clinical workflow while they are tending to their patients or prescribing them a drug improves manifold the chances of writing a brand’s script. If non-endemic media does not serve the purpose, which ‘script generation media’ does the job? However, is ‘lead generation media’ best suited for life sciences marketers whose end goal is to get scripts written? Through any campaign on digital, it is all they are looking to achieve. ![]() Eventually, it is about making the users fill in a contact form to capture the lead. For a consumer, it could mean downloading a whitepaper and case studies, participating in polls and surveys, or visiting a landing page. ![]() Non-endemic platforms - news, sports or a financial site for instance - have become quite popular mediums to reach the target audience and get them to take a desired action. With accelerated adoption of digital in the life sciences industry, marketers are rigorously working to generate leads through online mediums. It is crucial for life sciences brands to engage with healthcare professionals (HCPs) at appropriate moments to make them aware about their drugs and therapies, and additionally support them with relevant research around their area of expertise. Join me during my session to learn about my Medical Affairs experience, learn about what has gone well and what has not! Finally, it is an exciting journey that may soon expand to the metaverse. For instance, we’ve managed to develop the first voice assistant for Pharma which works with Google Assistant, and have gained a lot of learnings. How about “voice tech” or “digital voice virtual assistants?” There is no doubt in my mind that both voice and audio are new horizons with significant runway to completely transform customer-centricity and disrupt how pharma has previously engaged with customers. For example, take the role of virtual assistants, such as AI-enabled smart chatbots and how they can offer the opportunity to optimize the way HCPs can get answers instantaneously 24/7 on their computers or phones for their inquiries to make the best medical decisions for their patients. We (MA) stumble upon many limitations (i.e., On & Off label communications, Pharmacovigilance requirements, Proactive vs Reactive Communication, …etc.), oftentimes leading to the decision not to do anything!ĭisruptive digital technologies are always an exciting topic when thinking futuristically. But what about Medical Affairs? Many Medical teams are prudent to take the initiative-and risk-to make a difference in Medical Affairs Digital Communication either with HCPs or even with patients/caregivers. There has been exponential growth in digital communications fueling an external ecosystem of Marketing in Pharma. SymmetryRx has filled that space to the benefit of patients by complementing pharma rep services and removing relationship barriers often introduced by system technology. Until now, the ease of drug sampling digital technology that encompasses the needs of prescribers, their organizations, and pharma manufacturers has been a space needing to be filled. The productive dialogues often happen during the drug sample transaction. Prescribers and pharma manufacturers value the personal relationships afforded by pharma sales teams to engage and serve prescribers. Pharma manufacturers want access to prescribers to educate on proper use of their products and to offer patient support materials (educational and financial). Prescribers and practice owners want a process that meets their compliance obligations, is efficient, and provides risk management tools like recall reporting at the patient level. This is of concern to prescribers and pharma manufacturers. Barriers to drug sample acceptance by practices impacts patients. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |